Helus Pharma
Phase III2 active candidates
2 shared compoundssame indication: Major Depressive Disorder (MDD)same regulator: US FDAsimilar active pipeline size
Back to StakeholdersProgramme tracker View landscape
Lead program: Discovery
Categories
1 domain / 2 areas / 1 specialization
CB Therapeutics
Data updated
2 Drug Candidates
CB Therapeutics is a Carlsbad, California-based synthetic biology company developing biosynthetic psychedelic compounds and their novel analogues using a proprietary yeast fermentation platform. Founded in 2015, the company has raised $11.62M from investors including Y Combinator, Pioneer Fund, and re.Mind Capital. CB Therapeutics has achieved biosynthesis of psilocybin, psilocin, DMT, and MDMA analogs, holds seven granted patents with twelve pending, and has partnered with atai Life Sciences and Cleveland Clinic for clinical supply. Its PsyVault™ platform houses the largest collection of biosynthetic psychedelics and analogues.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 2
- Active programmes
- 2
- Lead stage
- Discovery
- Forecast coverage
- 2 of 2
All tracked candidates active
All tracked programmes active
Current furthest stage
2 active programmes with forecast fields
Latest sourced update
CB Therapeutics — Precision Synthetic Biology
Jun 26, 2026 - company-website - CB Therapeutics - Biosynthetic Psilocybin
Next known catalyst
preclinical-data
Timing not specified - Biosynthetic Psilocybin / Biosynthetic Psilocybin / Tryptamine Platform - Confidence: 25%
7 sources0 pipeline-linked trials0 pipeline-linked papers
Development Programmes
2Biosynthetic Psilocybin
PsilocybinDiscovery
Mental health (TRD / depression) — biosynthetic supply platform
Programme Tracker
Major Depressive Disorder (MDD)
Primary: US (FDA)
DiscoveryActive
Forecast
preclinical-data
Precision fermentation platform for psilocybin, DMT, and tryptamine analogues. Cleveland Clinic MOU (2020) for clinical trial supply. No clinical trials initiated. No public updates since mid-2020.
Milestones
Discovery completed
CompletedActual: Dec 4, 2019
CB Therapeutics achieved breakthrough biosynthesis of psilocybin, psilocin, and related tryptamines via engineered yeast fermentation
Why it matters: Biosynthetic production of psilocybin via fermentation could dramatically reduce cost vs. chemical synthesis or botanical extraction. CB Therapeutics was among the first companies to demonstrate GMP-viable fermentation routes for psychedelic compounds.
Watch next: GMP manufacturing scale-up, clinical trial supply agreements
Discovery completed
CompletedActual: Jun 3, 2020
Biosynthesis breakthrough for DMT and related tryptamine compounds announced
Why it matters: Expanded the fermentation platform beyond psilocybin to DMT and tryptamine derivatives, broadening potential supply applications.
Licensing deal
CompletedActual: Apr 20, 2020
Collaboration MOU signed with Cleveland Clinic for clinical trial supply of psilocybin, DMT, and MDMA analogues
Why it matters: Cleveland Clinic partnership validated the biosynthetic platform for clinical-grade supply. However, no clinical trials have been publicly registered from this collaboration as of April 2026 — the MOU may be dormant.
Recorded Events
Jun 3, 2020: Discovery completed
Apr 20, 2020: Licensing deal
Dec 4, 2019: Discovery completed
Evidence Links
CB Therapeutics — Precision Synthetic Biology
company-website - CB Therapeutics - Jun 26, 2026 - Verified
Current 2026 website positions CBT as a precision fermentation platform for rare molecules and mental-health compounds.
CB Therapeutics Achieves Biosynthesis of Psilocybin, Psilocin and Related Tryptamines
Press release - BioSpace - Dec 4, 2019 - Verified
CB Therapeutics Collaboration Agreement with Cleveland Clinic
Press release - Business Wire - Apr 20, 2020 - Verified
DMT Analogues
DMTDiscovery
Depression / anxiety — biosynthetic DMT analogue library
Programme Tracker
Major Depressive Disorder (MDD)
Primary: Other
DiscoveryActive
Forecast
preclinical-data
Discovery/supply-platform programme. CB Therapeutics has demonstrated DMT and tryptamine analogue biosynthesis in yeast and now presents TryptageniX as a rare-alkaloid precision-fermentation programme; no sponsor-led clinical trial has been disclosed.
Milestones
Discovery completed
CompletedActual: Jun 3, 2020
CB Therapeutics announced successful biosynthesis of DMT and related tryptamine-based compounds in yeast and patent filing around the production process.
Why it matters: Establishes the technical basis for DMT/tryptamine supply, but does not establish a clinical drug-development programme by itself.
Watch next: Named pharmaceutical partner, GMP supply contract, or clinical-trial sponsorship using CBT-produced material.
Recorded Events
Jun 3, 2020: Discovery completed
Evidence Links
CB Therapeutics — Precision Synthetic Biology
company-website - CB Therapeutics - Jun 26, 2026 - Verified
CB Therapeutics Achieves Biosynthesis of DMT and Related Tryptamines
Press release - Business Wire - Jun 3, 2020 - Verified
CB Therapeutics — TryptageniX Program
company-website - CB Therapeutics - Jun 26, 2026 - Verified
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
Entheos Labs
Discovery1 active candidate
2 shared indicationsDiscovery peersame regulator: US FDAsimilar active pipeline size
Elkedonia
Discovery1 active candidate
2 shared indicationsDiscovery peersimilar active pipeline sizeboth have forecast coverage
Remedi Therapeutics
Preclinical2 active candidates
2 shared indicationssame regulator: US FDAsimilar active pipeline sizeboth have forecast coverage
Quick Facts
- Type
- Private Biotech
- Founded
- 2015
- Lead Stage
- Discovery
- Website
- Visit